<DOC>
	<DOCNO>NCT02589457</DOCNO>
	<brief_summary>The purpose study compare safety pharmacokinetics CKD-390 ( Tenofovir Disoproxil Aspartate ) Viread® tablet ( Tenofovir Disoproxil Fumarate ) healthy male volunteer .</brief_summary>
	<brief_title>Study Compare Safety Pharmacokinetics CKD-390 Tablet With Viread® Tablet</brief_title>
	<detailed_description>A Randomized , Open-label , Single-dosing , 2x2 Crossover Study Compare Safety Pharmacokinetics CKD-390 Tablet ( Tenofovir Disoproxil Aspartate ) With Viread® Tablet ( Tenofovir Disoproxil Fumarate ) Healthy Male Volunteers</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Healthy male volunteer age 1945 2 . Body weight ≥ 55kg range calculate Ideal Body Weight ± 20 % 3 . Subject without hereditary problem , chronic disease morbid symptom 4 . Subject sign inform consent form willingly 1 . Clinically significant disease hepatobiliary , nephrological , gastrointestinal , respiratory , hepatooncological , endocrine , urogenital , neurologic , psychiatric , musculoskeletal , immune , otorhinolaryngological , cardiovascular system 2 . Gastrointestinal disease ( Crohn 's disease , ulcer , acute/chronic pancreatitis ) gastrointestinal surgery ( except appendectomy herniotomy ) 3 . Hypersensitivity reaction clinically significant hypersensitivity reaction history drug additives 4 . Galactose intolerance , Lapp lactase deficiency Glucosegalactose malabsorption 5 . Sitting systolic blood pressure &gt; 140mmHg &lt; 100mmHg , sit diastolic blood pressure ≥ 90mmHg &lt; 60mmHg , pulse ≥ 100 beat per minute 6 . Aspartate aminotransferase , Alanine aminotransferase , Total bilirubin &gt; 2 x upper limit normal range 7 . Have result Creatinine clearance less 50mL/min ( CockcroftGault equation applicable ) 8 . The history drug abuse drug abuse show positive urine drug test 9 . Subject treat metabolize enzyme inducer inhibitor include barbiturate within 1 month 10 . Subject treat ethical counter herbal medicine within 2 week , overthecounter vitamin within 1 week 11 . Taking drug receive investigational drug within 3 month prior first dose 12 . Whole blood donation within 2 month prior first dose component blood donation within 1 month prior first dose blood transfusion within 1 month 13 . Continuously take excessive alcohol ( &gt; 21 units/week ; 1 unit = 10g pure alcohol ) stop drink 24 hour admission discharge 14 . Cigarette &gt; 10 cigarette day average recent 3 month 15 . Subjects plan dental treatment ( tooth extraction , endodontic treatment etc . ) surgery ( aesthetic operation , laser insitu keratomileusis , laser assist subepithelial keratomileusis etc . ) sign informed consent form poststudy visit 16 . An impossible one participant clinical trial investigator 's decision include laboratory test result another reason</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Chronic Hepatitis B virus , HIV-1 infection</keyword>
	<keyword>Healthy Male Volunteer</keyword>
	<keyword>Tenofovir Disoproxil Fumarate</keyword>
</DOC>